Editorial Comment on ‘Limited success with Clostridium Collagenase Histolyticum following FDA approval for the treatment of Peyronie’s disease’
Crossref DOI link: https://doi.org/10.1038/s41443-018-0086-7
Published Online: 2018-10-17
Published Print: 2019-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tal, Raanan
Text and Data Mining valid from 2018-10-17
Article History
Received: 13 September 2018
Accepted: 19 September 2018
First Online: 17 October 2018
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.